CN106665560B - Immune cell frozen stock solution for direct venous return and application thereof - Google Patents
Immune cell frozen stock solution for direct venous return and application thereof Download PDFInfo
- Publication number
- CN106665560B CN106665560B CN201710028750.3A CN201710028750A CN106665560B CN 106665560 B CN106665560 B CN 106665560B CN 201710028750 A CN201710028750 A CN 201710028750A CN 106665560 B CN106665560 B CN 106665560B
- Authority
- CN
- China
- Prior art keywords
- cells
- solution
- cryopreservation
- immune
- immune cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 54
- 239000011550 stock solution Substances 0.000 title claims abstract description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 52
- 210000004027 cell Anatomy 0.000 claims abstract description 52
- 238000005138 cryopreservation Methods 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 35
- 238000007710 freezing Methods 0.000 claims abstract description 23
- 230000008014 freezing Effects 0.000 claims abstract description 23
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims abstract description 21
- 229940050526 hydroxyethylstarch Drugs 0.000 claims abstract description 21
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 229920000669 heparin Polymers 0.000 claims abstract description 17
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims abstract description 17
- 229960001008 heparin sodium Drugs 0.000 claims abstract description 17
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 14
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 14
- 229920002307 Dextran Polymers 0.000 claims abstract description 13
- 238000001802 infusion Methods 0.000 claims abstract description 11
- 238000001990 intravenous administration Methods 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 57
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- 238000010999 medical injection Methods 0.000 claims description 14
- 239000008103 glucose Substances 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 210000000822 natural killer cell Anatomy 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 239000012595 freezing medium Substances 0.000 claims description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 239000008227 sterile water for injection Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 239000002994 raw material Substances 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 4
- 239000000427 antigen Substances 0.000 abstract description 3
- 102000036639 antigens Human genes 0.000 abstract description 3
- 108091007433 antigens Proteins 0.000 abstract description 3
- 238000002659 cell therapy Methods 0.000 abstract description 2
- 229960002086 dextran Drugs 0.000 abstract description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 19
- 239000000306 component Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 229940090044 injection Drugs 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 229940119744 dextran 40 Drugs 0.000 description 9
- 239000008354 sodium chloride injection Substances 0.000 description 8
- 229940093181 glucose injection Drugs 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007447 staining method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940087603 grape seed extract Drugs 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012534 cell culture medium component Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011066 ex-situ storage Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
Abstract
The invention discloses immune cell frozen stock solution for direct venous return and application thereof. The invention adopts the raw materials of clinical medicine grade such as dimethyl sulfoxide, human serum albumin, dextran, hydroxyethyl starch, heparin sodium and the like, and finally prepares the immune cell frozen stock solution for direct intravenous infusion by optimizing the use amount of each raw material. In addition, the invention also simplifies the operation steps and improves the freezing and storing effect by optimizing the freezing and storing method. On one hand, the invention avoids the potential risk of introducing animal-derived antigen substances in the cell treatment process; on the other hand, the immune cell cryopreservation effect of the invention is better than that of the conventional cryopreservation liquid, thereby ensuring the safety and effectiveness of clinical use. The invention can store the frozen stock solution stably for a long time by storing the two components. The method is simple to operate, provides stronger operability for implementation of large-scale cryopreservation, and provides basic technical support for implementation of immune cell therapy.
Description
Technical Field
The invention relates to a cell cryopreservation solution, in particular to an immune cell cryopreservation solution for direct venous return and an application method thereof. The invention belongs to the technical field of biological medicines.
Background
Cancer is the primary problem which afflicts human health, and cellular immunotherapy provides a broad prospect for the prevention and treatment of tumors. However, in the process of clinical practical application, there are many problems that autoimmune cells of some tumor patients are difficult to collect, the cell expansion capability is poor, the time windows of the immune cells and other treatment modes are difficult to match, and the like; in addition, ex situ transport, storage conditions and survival time of fresh immune cells are limited from the standpoint of drug development and production. Therefore, the effective cryopreservation of the immune cells provides necessary basic technical guarantee for the industrial application of the immune cells as medicines.
However, most of the currently marketed immune cell frozen stocks are prepared from fetal bovine serum, high-proportion DMSO, autologous patient plasma and non-clinical application-level reagents, and the frozen stocks have the following problems: 1. the freezing effect is poor; 2. the frozen stock solution has undefined components; 3. the cryopreservation process and subsequent application programs are relatively complicated; 4. the cost is too high; 5. there is a risk in clinical use; 6. is not suitable for industrialization. For example:
the patent application with the publication number of CN104026118A discloses an immune cell freezing solution, a preparation method and an application thereof, wherein dimethyl sulfoxide, inactivated human autologous plasma and immune cell culture medium components are used for freezing immune cells by a programmed cooling method. The technical problems are that the cryopreservation liquid of the application uses autologous plasma inactivated by a patient, the quantity and the source are limited, the cryopreservation liquid is not suitable for large-scale cryopreservation after cell amplification culture, the cryopreservation process is complicated, and batch control is difficult.
Patent application with publication number CN105248413A discloses a CIK cell cryopreservation solution, which uses dimethyl sulfoxide, grape seed extract, raffinose, human serum albumin, and fetal bovine serum to cryopreserve CIK cells. The technical problem is that the frozen stock solution contains animal-derived serum, has potential risk of introducing animal-derived antigen substances, and cannot be directly returned to a human body.
Patent application publication No. CN105211051A discloses a frozen stock solution of cultured NK cells and a preparation method thereof, wherein dimethyl sulfoxide, inactivated human autologous plasma, and grape seed extract, tea polyphenol and vitamin C are added as components of the frozen stock solution. The technical problem is that the cryopreservation solution of the application uses autologous inactivated plasma of a patient, has limited quantity and source and is not suitable for large-scale cryopreservation after cell amplification culture.
Patent application with publication number CN105123671A discloses a cell cryopreservation liquid, application and an immune cell cryopreservation method, wherein dimethyl sulfoxide, propylene glycol, a cell culture medium, human serum albumin are used as components of the cryopreservation liquid, and non-essential amino acid, trehalose, lentinan and vitamin C are added. The technical problem is that the main component of the frozen stock solution is a cell culture medium, does not have the effect of a stabilizer and cannot be directly used for clinical reinfusion.
The patent application with publication number CN104862275A discloses a method for freezing and recovering cells and a cell preparation prepared by the method, wherein dimethyl sulfoxide, 1640 cell basal medium, fetal calf serum, dextran and ddH2O are used as components of a freezing solution. The technical problem is that the frozen stock solution contains animal-derived serum, has potential risk of introducing animal-derived antigen substances, and cannot be directly returned to a human body.
In conclusion, the effective components of the existing freezing medium mostly contain scientific research-grade cell culture medium, fetal bovine serum and other components, can not be directly applied to human infusion, and is expensive. Therefore, there is a need to research a frozen immune cell stock solution with better frozen effect, lower price, more convenient use and safer application.
Disclosure of Invention
The invention aims to solve the technical problems of poor freezing effect, undefined freezing solution component, relatively complicated freezing process and subsequent application program, high cost, risk in clinical application, unsuitability for large-scale production and the like in the prior art, and provides the immune cell freezing solution for direct intravenous return transfusion and the application method thereof.
In order to achieve the purpose, the invention adopts the following technical means:
the immune cell frozen stock solution directly transfused by vein of the invention is composed of solution A and solution B, wherein, the solution A contains the following components: 4-16 v/v% of dimethyl sulfoxide, 0.3-5.5 w/v% of hydroxyethyl starch, 0.3-5.5 w/v% of dextran, 0.5-5 w/v% of glucose, 1-1000U/ml of heparin sodium and the balance of medical injection; the B solution is medical injection containing 2-25 w/v% human serum albumin.
In the present invention, the content of each component in the solution a is preferably: 8.3 v/v% of dimethyl sulfoxide, 2.75 w/v% of hydroxyethyl starch, 2.75 w/v% of dextran, 2.29 w/v% of glucose, 625U/ml of heparin sodium and the balance of medical injection; the B solution is medical injection containing 20 w/v% human serum albumin.
In the present invention, preferably, the medical injection solution includes, but is not limited to: one or more of sterile water for injection, physiological saline, electrolyte injection, dextran injection or hydroxyethyl starch sodium chloride injection.
The raw materials for preparing the frozen stock solution can be raw material medicines or finished products of medicines prepared by solution. For example, the hydroxyethyl starch can be hydroxyethyl starch sodium chloride injection, the dextran and the glucose can be dextran 40 glucose injection, and the heparin sodium can be heparin sodium injection. As long as the final concentration of the active ingredient satisfies the above requirements.
The invention is prepared by optimizing the mixture ratio of dimethyl sulfoxide, human serum albumin, dextran, hydroxyethyl starch and heparin sodium, and adopting raw materials of clinical medicinal grade and medical injection. On one hand, the risk of pollution of animal-derived substances is avoided, and on the other hand, the immune cell cryopreservation effect is better than that of the conventional cryopreservation liquid. Thereby ensuring the safety and effectiveness of clinical use. In addition, the method is simple to operate, is suitable for implementation of large-scale cryopreservation, can be directly infused after cell resuscitation, and is convenient for clinical implementation.
Furthermore, the invention also provides application of the cryopreservation liquid in cryopreservation of immune cells.
Among them, preferably, the immune cells include but are not limited to: t cells, NK cells, monocytes, DC cells, γ δ T cells, CAR-T cells.
Furthermore, the invention also provides a method for freezing and storing immune cells in vitro, which comprises the following steps:
1) uniformly mixing the solution A and the solution B of the frozen stock solution according to the volume ratio of 3:2, and placing the mixture in a refrigerator for precooling at 4 ℃;
2) collecting immune cells to be frozen and washing twice;
3) re-suspending the immune cells by using a pre-cooled freezing medium, transferring the immune cells into a freezing bag, and placing the immune cells in a refrigerator at 4 ℃ for balancing or directly performing the step 4) by skipping the balancing step if the operation time of the step 3) is longer than 30 min;
4) the freezing bag with the cells is placed in a refrigerator at minus 80 ℃ overnight and then transferred to a liquid nitrogen tank for long-term storage.
In the present invention, it is preferable that the cryopreserved immune cells are used by rapidly taking out the cryopreserved bag from a liquid nitrogen tank, placing the cryopreserved bag in a water bath at 37 ℃ until the cryopreserved bag is completely thawed, and completing intravenous infusion within 1 hour after thawing.
In the present invention, it is preferable that the time for the refrigerator equilibration at 4 ℃ is 1-30 min.
In the present invention, preferably, the immune cells include, but are not limited to: t cells, NK cells, monocytes, DC cells, γ δ T cells, CAR-T cells.
In the present invention, preferably, the freezing density of the immune cells is 1 × 106/ml-1×108/ml。
Compared with the prior art, the invention has the beneficial effects that:
the invention overcomes the defects of poor freezing effect, undefined freezing medium component, relatively complicated freezing process and subsequent application program, high cost, risk in clinical application, unsuitability for large-scale production and the like in the prior art, and provides the immune cell freezing medium for direct venous return and the application method thereof.
Compared with the conventional freezing method: 1. compared with freshly cultured immune cells, the immune cells recovered by the method have no significant difference in immunobiological characteristics (cell viability, apoptosis level, immunophenotype and the like) and biological functions (killing effect on target cells, cytokine secretion level and the like); 2. the frozen stock solution has definite raw materials, no animal-derived components, clinical medicinal grade and clinical application safety; 3. patient autologous plasma is not used, the quantity and source of raw materials are not limited, the cost is low, and the method is suitable for industrialization; 4. the frozen stock solution has good storage stability through a component storage mode; the DMSO content is relatively low, and the cytotoxicity of the DMSO in the frozen stock solution is reduced by precooling the frozen stock solution; 6. the freezing and storing process of the immune cells does not need long-time programmed cooling; 7. after resuscitation, the conventional centrifugal cleaning step is not needed, and venous return transfusion can be directly carried out, thereby greatly facilitating clinical application.
In conclusion, the invention abandons the components which are not suitable for clinical use in the conventional frozen stock solution, selects the clinically common medicines to prepare the frozen stock solution through scientific proportion, simplifies the preparation operation of the frozen stock solution through a scientific storage mode, simplifies the operation steps through an optimized frozen stock method, improves the frozen stock effect and provides basic guarantee for the implementation of immune cell therapy. Compared with the prior art, the invention has high safety, does not contain animal-derived serum with potential pathogenic risk, and can be stably stored for a long time by the two components. The cryopreservation method is simple and easy to implement, can meet the requirements of clinical large-scale operation, is superior to the conventional cryopreservation method in cryopreservation effect, can be directly infused after cells are recovered, and reduces the damage to the cells caused by intermediate complicated treatment links and washing. And the raw material cost is low, the method is suitable for industrial production, and great economic benefit can be generated.
Detailed Description
The present invention is further illustrated by the following specific examples, which are intended to be illustrative, not limiting and are not intended to limit the scope of the invention.
Example 1: preparation and application of immune cell frozen stock solution for direct intravenous infusion
1. Raw materials and specifications
Hydroxyethyl starch sodium chloride injection: 500ml of hydroxyethyl starch (200/0.5)30g
Dextran 40 glucose injection: 500ml of 30g of dextran 40 and 25g of glucose
Heparin sodium injection: 2ml:1.25 ten thousand units
Human serum albumin injection: 50 ml: 10g Total protein
2. Preparation and application of immune cell frozen stock solution for direct intravenous infusion
1) Respectively preparing solution A and solution B
Solution a (100 ml): 8.3ml of dimethyl sulfoxide, 45.8ml of hydroxyethyl starch and sodium chloride injection, 45.8ml of dextran 40 and glucose injection and 0.1ml of heparin sodium injection.
The content of each component in the solution A is as follows: 8.3 v/v% of dimethyl sulfoxide, 2.75 w/v% of hydroxyethyl starch, 2.75 w/v% of dextran, 2.29 w/v% of glucose, 625U/ml of heparin sodium and the balance of medical injection.
Solution B (100 ml): 20 w/v% human serum albumin injection.
2) Mixing the solution A and the solution B in a volume ratio of 3:2, and placing in a refrigerator at 4 ℃ for later use.
3) 50ml of peripheral blood of healthy volunteers is extracted, slowly added into a centrifuge tube filled with lymphocyte separation liquid, centrifuged for 20 minutes at 500g, and leucocyte layer cells are sucked. Washed twice with PBS and counted.
4) Based on the counting result, use2) Resuspending PBMC cells in a well-prepared, pre-cooled frozen stock solution to a cell density of 1X 107Perml, transfer cells to cryopreservation bags.
5) The frozen bag with cells was placed in a refrigerator at 4 ℃ and equilibrated for 15 min.
6) The frozen bags containing the cells were placed in a-80 ℃ freezer overnight.
6) And (4) placing the cryopreservation bag containing the cells into liquid nitrogen for preservation.
7) Taking out cells from a liquid nitrogen tank after 1, 6 and 12 months, placing the cells in a water bath kettle at 37 ℃ for thawing, taking a small amount of cells, and detecting the cell viability by a trypan blue staining method.
PBMC cells treated with control cryopreservation (50% FBS + 40% RPMI1640+ 10% DMSO) were also used as controls, and the procedure was the same as above except for the cryopreservation.
3. Results
A comparison of PBMC resuscitation activity rates with different freezing media is shown in table 1:
TABLE 1 comparison of PBMC resuscitation Activity rates with different cryopreservation fluids
| The cryopreservation liquid of the invention | Control frozen stock solution | |
| Survival rate of 1 month | 98.5％ | 87.1％ |
| Survival rate of 6 months | 96.2％ | 85.4％ |
| Survival rate of 12 months | 93.7％ | 80.7％ |
Example 2 preparation and application of immune cell cryopreservation solution for direct intravenous infusion
1. Raw materials and specifications
Hydroxyethyl starch sodium chloride injection: 500ml of hydroxyethyl starch (200/0.5)30g
Dextran 40 glucose injection: 500ml of 30g of dextran 40 and 25g of glucose
Heparin sodium injection: 2ml:1.25 ten thousand units
Human serum albumin injection: 50 ml: 5g Total protein
2. Preparation and application of immune cell frozen stock solution for direct intravenous infusion
1) Respectively preparing solution A and solution B
Solution a (100 ml): 10ml of dimethyl sulfoxide, 70ml of hydroxyethyl starch and sodium chloride injection, 19.9ml of dextran 40 and glucose injection and 0.1ml of heparin sodium injection
The content of each component in the solution A is as follows: 10 v/v% of dimethyl sulfoxide, 4.2 w/v% of hydroxyethyl starch, 1.19 w/v% of dextran, 1.0 w/v% of glucose, 625U/ml of heparin sodium and the balance of medical injection;
solution B (100 ml): 10 w/v% human serum albumin injection
2) And uniformly mixing the solution A and the solution B according to the volume ratio of 3:2, and placing the mixture in a refrigerator at 4 ℃ for later use.
3) And (4) taking the cultured and amplified NK cells to a centrifuge tube, and centrifuging for 10min at 300 g. Washed twice with PBS and counted.
4) According to the counting result, the NK cells are re-suspended by using the frozen stock solution prepared and pre-cooled in the step 2) so that the cell density is 1 multiplied by 108Perml, transfer cells to cryopreservation bags.
5) The freezing bag with the cells is placed in a 4-degree refrigerator to be balanced for 15 min.
6) The frozen bags containing the cells were placed in a-80 ℃ freezer overnight.
6) And (4) placing the cryopreservation bag containing the cells into liquid nitrogen for preservation.
7) Taking out cells from a liquid nitrogen tank after 1, 6 and 12 months, placing the cells in a water bath kettle at 37 ℃ for thawing, taking a small amount of cells, and detecting the cell viability by a trypan blue staining method.
NK cells were also treated with a control cryopreservation solution (50% FBS + 40% RPMI1640+ 10% DMSO) as a control, and the procedure was the same as above except for the cryopreservation solution.
3. Results
Comparison of NK resuscitation activity with different frozen stocks is shown in table 2:
TABLE 2 comparison of NK cell resuscitative Activity rates with different cryopreservation solutions
| Example 2 | Example 2 comparison | |
| Survival rate of 1 month | 96.4％ | 82.6％ |
| Survival rate of 6 months | 92.8％ | 75.3％ |
| Survival rate of 12 months | 90.5％ | 60.2％ |
Example 3 preparation and application of immune cell cryopreservation solution for direct intravenous infusion
1. Raw materials and specifications
Hydroxyethyl starch sodium chloride injection: 500ml of hydroxyethyl starch (200/0.5)30g
Dextran 40 glucose injection: 500ml of 30g of dextran 40 and 25g of glucose
Heparin sodium injection: 2ml:1.25 ten thousand units.
Human serum albumin injection: 50 ml: 5g Total protein
2. Preparation and application of immune cell frozen stock solution for direct intravenous infusion
1) Respectively preparing solution A and solution B
Solution a (100 ml): 9ml of dimethyl sulfoxide, 33ml of hydroxyethyl starch and sodium chloride injection, 57.9ml of dextran glucose injection and 0.1ml of heparin sodium injection.
The content of each component in the solution A is as follows: 9 v/v% of dimethyl sulfoxide, 1.98 w/v% of hydroxyethyl starch, 3.47 w/v% of dextran, 2.9 w/v% of glucose, 625U/ml of heparin sodium and the balance of medical injection;
solution B (100 ml): 10 w/v% human serum albumin injection.
2) Mixing solution A and solution B at ratio of 3:2, and placing in refrigerator at 4 deg.C for use.
3) And taking the CAR-T cells after culture and amplification into a centrifuge tube, and centrifuging for 10min at 300 g. Washed twice with PBS and counted.
4) According to the counting results, the CAR-T cells were resuspended in the prepared, precooled cryopreservation solution of 2) so that the cell density was 5X 107Perml, transfer cells to cryopreservation bags.
5) The frozen bag with cells was placed in a refrigerator at 4 ℃ and equilibrated for 15 min.
6) The frozen bags containing the cells were placed in a-80 ℃ freezer overnight.
6) And (4) placing the cryopreservation bag containing the cells into liquid nitrogen for preservation.
7) Taking out cells from a liquid nitrogen tank after 1, 6 and 12 months, placing the cells in a water bath kettle at 37 ℃ for thawing, taking a small amount of cells, and detecting the cell viability by a trypan blue staining method.
CAR-T cells treated with control cryopreservation (50% FBS + 40% RPMI1640+ 10% DMSO) were also used as controls, except for the cryopreservation.
3. Results
A comparison of CAR-T resuscitation activity rates with different cryopreservation fluids is shown in Table 3:
TABLE 3 CAR-T cell Resuscitation Activity comparisons with different cryopreservatives
| Example 3 | Example 3 comparison | |
| Survival rate of 1 month | 98.1％ | 85.5％ |
| Survival rate of 6 months | 96.7％ | 80.5％ |
| Survival rate of 12 months | 93.3％ | 72.4％ |
The above examples are merely illustrative of the present invention and should not be construed as limiting the invention. Modifications or substitutions to methods, procedures, or conditions of the invention may be made without departing from the spirit and scope of the invention.
Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.
Claims (13)
1. The immune cell frozen stock solution for direct intravenous infusion is characterized by consisting of a solution A and a solution B, wherein the solution A contains the following components: 8.3-10 v/v% of dimethyl sulfoxide, 1.98-4.2 w/v% of hydroxyethyl starch, 1.19-3.47 w/v% of dextran, 1.0-2.9 w/v% of glucose, 625U/ml of heparin sodium and the balance of medical injection; the B solution is a medical injection containing 10-20 w/v% human serum albumin, the medical injection is one or two of sterile water for injection and physiological saline, and the volume ratio of the A solution to the B solution is 3: 2.
2. The cryopreservation solution of claim 1, wherein the contents of the components in the solution A are as follows: 8.3 v/v% of dimethyl sulfoxide, 2.75 w/v% of hydroxyethyl starch, 2.75 w/v% of dextran, 2.29 w/v% of glucose, 625U/ml of heparin sodium and the balance of medical injection; the B solution is medical injection containing 20 w/v% human serum albumin.
3. Use of the cryopreservation solution of claim 1 or 2 for cryopreservation of immune cells.
4. The use of claim 3, wherein said immune cells comprise: PBMC cells.
5. The use of claim 3, wherein said immune cells comprise: t cells, NK cells, DC cells.
6. The use of claim 5, wherein said T cells comprise: γ δ T cells, CAR-T cells.
7. A method for freezing immune cells in vitro is characterized by comprising the following steps:
1) uniformly mixing the solution A and the solution B of the frozen stock solution according to the volume ratio of 3:2, and placing the mixture in a refrigerator for precooling at 4 ℃;
2) collecting immune cells to be frozen and washing twice;
3) re-suspending the immune cells by using a pre-cooled freezing medium, transferring the immune cells into a freezing bag, and placing the immune cells in a refrigerator at 4 ℃ for balancing or directly performing the step 4) by skipping the balancing step if the operation time of the step 3) is longer than 30 min;
4) the freezing bag with the cells is placed in a refrigerator at minus 80 ℃ overnight and then transferred to a liquid nitrogen tank for long-term storage.
8. The method of claim 7, wherein the cryopreserved immune cells are used by rapidly removing the cryopreserved bag from a liquid nitrogen tank, placing the cryopreserved bag in a water bath at 37 ℃ until the cryopreserved bag is completely thawed, and completing the intravenous infusion within 1 hour after thawing.
9. The method of claim 7, wherein the time to equilibrate in a 4 ℃ freezer is 15 min.
10. The method of claim 7, wherein the immune cell comprises: PBMC cells.
11. The method of claim 7, wherein the immune cell comprises: t cells, NK cells, DC cells.
12. The method of claim 11, wherein said T cell comprises: γ δ T cells, CAR-T cells.
13. The method of claim 7, wherein said immune cells are cryopreserved at a density of 1 x 107/ml-1×108/ml。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710028750.3A CN106665560B (en) | 2017-01-16 | 2017-01-16 | Immune cell frozen stock solution for direct venous return and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710028750.3A CN106665560B (en) | 2017-01-16 | 2017-01-16 | Immune cell frozen stock solution for direct venous return and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106665560A CN106665560A (en) | 2017-05-17 |
| CN106665560B true CN106665560B (en) | 2021-02-05 |
Family
ID=58859055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710028750.3A Active CN106665560B (en) | 2017-01-16 | 2017-01-16 | Immune cell frozen stock solution for direct venous return and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106665560B (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108925548A (en) * | 2017-05-24 | 2018-12-04 | 西比曼生物科技（香港）有限公司 | A kind of freeze-stored cell preparation and cell recovery mode |
| CN107347871A (en) * | 2017-06-07 | 2017-11-17 | 江苏善之源健康科技有限公司 | A kind of immunocyte, which is fed back, preserves liquid |
| CN107094754A (en) * | 2017-06-15 | 2017-08-29 | 蓝石科技有限公司 | A kind of Human Active's immunocyte frozen stock solution and its cryopreservation methods |
| CN107326015B (en) * | 2017-09-05 | 2020-04-03 | 四川汇宇制药有限公司 | CAR-T cell resuscitation method |
| CN107912420A (en) * | 2017-10-27 | 2018-04-17 | 北京协科医药科技有限公司 | A kind of cell preservation method, preserve liquid and preserve liquid and preparation method thereof |
| CN107970258B (en) * | 2017-11-20 | 2020-11-10 | 英普乐孚生物技术(上海)有限公司 | Chimeric antigen receptor T cell preparation |
| CN107912425B (en) * | 2017-12-06 | 2020-12-08 | 湖南昭泰涌仁医疗创新有限公司 | Cell cryopreservation tube kit capable of being used for transfusion and application thereof |
| CN108378021A (en) * | 2018-03-19 | 2018-08-10 | 英普乐孚生物技术(上海)有限公司 | A kind of stored refrigerated system of lymphocyte |
| CN108552160A (en) * | 2018-05-04 | 2018-09-21 | 武汉波睿达生物科技有限公司 | A kind of CAR-T cells frozen storing liquids of direct venous re-transfusion and its preparation method and application |
| CN108552159A (en) * | 2018-05-04 | 2018-09-21 | 武汉波睿达生物科技有限公司 | A kind of frozen stock solution for being used for CAR-T clinical grades Cord blood and being directly injected intravenously feedback |
| CN108617640A (en) * | 2018-06-26 | 2018-10-09 | 吉林省太阳鸟再生医学工程有限责任公司 | A kind of cord blood mononuclear cells frozen stock solution and its application |
| CN109744226A (en) * | 2018-12-30 | 2019-05-14 | 深圳光彩生命工程技术有限公司 | A kind of immunocyte frozen stock solution |
| CN110100812A (en) * | 2019-05-30 | 2019-08-09 | 南京艾德免疫治疗研究院有限公司 | The freezing of a kind of immunocyte feeds back liquid, cryopreservation methods and feeds back application |
| CN110679588A (en) * | 2019-10-23 | 2020-01-14 | 厦门生命互联科技有限公司 | Chimeric antigen receptor T cell cryopreservation medium and application thereof |
| CN111387174A (en) * | 2020-01-17 | 2020-07-10 | 广东先康达生物科技有限公司 | Immune cell cryopreservation liquid and immune cell cryopreservation method |
| CN111387175A (en) * | 2020-05-06 | 2020-07-10 | 河北生命原点生物科技有限公司 | Cryopreservation solution and cryopreservation method for lymphoid cells |
| CN112042637A (en) * | 2020-09-17 | 2020-12-08 | 深圳普瑞金生物药业有限公司 | Cell cryopreservation agent and cell cryopreservation method |
| CN112353816A (en) * | 2020-11-10 | 2021-02-12 | 中国科学院大学宁波华美医院 | Freezing medium for stem cells and related products capable of being directly transfused |
| CN112450206A (en) * | 2020-12-24 | 2021-03-09 | 广东赛尔生物科技有限公司 | Non-programmed cell cryopreservation liquid for direct intravenous use |
| CN112806354A (en) * | 2021-01-18 | 2021-05-18 | 圣至同合(北京)生物科技有限公司 | Immune cell cryopreservation liquid as well as preparation method and application thereof |
| CN112806355A (en) * | 2021-01-20 | 2021-05-18 | 山东科硕生物技术有限公司 | Cell preservation solution and preparation method and application thereof |
| CN113615681A (en) * | 2021-08-27 | 2021-11-09 | 郑州源创吉因实业有限公司 | Frozen stock solution and frozen stock method for immune cells |
| CN115723990A (en) * | 2021-08-27 | 2023-03-03 | 上海赛比曼生物科技有限公司 | Fully-closed and fully-automatic cell subpackaging device and method |
| CN114041456B (en) * | 2021-12-09 | 2022-12-27 | 安徽中盛溯源生物科技有限公司 | Clinical-grade NK cell cryopreservation liquid and using method thereof |
| CN114271263A (en) * | 2021-12-30 | 2022-04-05 | 杭州芯递力生物科技有限公司 | Cell preservation solution, cryopreservation kit and cell cryopreservation method |
| CN115644168B (en) * | 2022-11-09 | 2024-03-01 | 湖南开启时代生物科技有限责任公司 | Frozen stock solution of finished immune cells, preparation method thereof and frozen stock method |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919614A (en) * | 1994-10-19 | 1999-07-06 | Lifecell Corporation | Composition comprising three platelet lesion inhibitors for platelet storage |
| CA2599274A1 (en) * | 2005-02-28 | 2006-09-08 | Regenetech, Inc. | Method of providing readily available cellular material derived from peripheral blood and a composition thereof |
| DE102005031532A1 (en) * | 2005-07-01 | 2007-01-04 | Cytonet Gmbh & Co. Kg | Storage medium for cells |
| CN101210232B (en) * | 2006-12-28 | 2012-07-18 | 天津昂赛细胞基因工程有限公司 | Mesenchyme stem cell preserving fluid |
| CN103563888B (en) * | 2013-10-31 | 2015-11-25 | 北京永泰生物制品有限公司 | Cells frozen storing liquid |
| CN103548814B (en) * | 2013-11-07 | 2015-04-08 | 中国人民解放军第三军医大学第一附属医院 | Non-programmable-controlled cooling cryopreservation method and protection agent for hematopoietic stem cells at minus 80DEG C |
| CN105660606B (en) * | 2016-03-10 | 2018-04-03 | 广州赛莱拉干细胞科技股份有限公司 | A kind of cells frozen storing liquid |
-
2017
- 2017-01-16 CN CN201710028750.3A patent/CN106665560B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106665560A (en) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106665560B (en) | Immune cell frozen stock solution for direct venous return and application thereof | |
| CN105123671B (en) | A kind of cells frozen storing liquid, using and immunocyte cryopreservation methods | |
| AU2014221330B2 (en) | Combined organ and hematopoietic cells for transplantation tolerance of grafts | |
| CN105076116A (en) | Cell cryopreservation liquid, application thereof and cryopreservation method of megakaryocyte progenitor cells | |
| US20110008300A1 (en) | Cryopreservation of Adipose Tissue for the Isolation of Mesenchymal Stem Cells | |
| CN104873542A (en) | Umbilical cord mesenchymal stem cell injection as well as preparation method and application thereof | |
| US11435350B2 (en) | Methods of analysis of blood from deceased donors | |
| CN109511648B (en) | Mesenchymal stem cell preservation solution for clinical local injection and method for preserving mesenchymal stem cells | |
| AU2016342387B2 (en) | Stem cell therapy based on adipose-derived stem cells | |
| EP2641623B1 (en) | Apparatus and methods for providing cryopreserved ecp-treated mononuclear cells | |
| JP2022502483A (en) | Cellular compositions derived from deceased donors and their manufacture and use to promote transplant immune tolerance | |
| JP2008531696A (en) | Methods and compositions for treating cardiac tissue | |
| Cannas et al. | Supportive care in patients with acute leukaemia: historical perspectives | |
| CN110974847A (en) | Method for treating lower limb ischemic diseases by using stem cells | |
| KR20080027295A (en) | Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use | |
| CN115039763A (en) | Immune cell cryopreservation liquid | |
| CN115226706A (en) | Cell cryopreservation liquid and cell cryopreservation and/or reinfusion method | |
| US20240115769A1 (en) | Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof | |
| CN101914497B (en) | Clinical N-CIK cell culture and quality control and identification kit and application | |
| US20190224494A1 (en) | Apparatus and method for batch photoactivation of mononuclear cells with cryopreservation | |
| CN110882276B (en) | Cell therapy compositions and methods for treating vascular disorders | |
| CN111449053A (en) | Immune cell storage liquid and preparation and application methods thereof | |
| US20200087627A1 (en) | Methods of extracting hematopoietic cells from bone marrow ex vivo | |
| US20200086004A1 (en) | Methods of making cellular compositions derived from deceased donors to promote graft tolerance | |
| Zubair et al. | Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231023 Address after: Room 216, Life Medicine Entrepreneurship Building, Limin Biopharmaceutical R&D Center, Shenyang Street East and Zhuhai Road South, Limin Development Zone, Harbin City, Heilongjiang Province, 150500 Patentee after: Zhongke Sai'er Biotechnology (Heilongjiang) Co.,Ltd. Address before: 150081 No. 157 health Road, Nangang District, Heilongjiang, Harbin Patentee before: HARBIN MEDICAL University |